Switch theme
Sign up to access all valuation multiples
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm's crop science business sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
1863
92.8K+
LTM Revenue $54.4B
LTM EBITDA $11.4B
$70.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bayer has a last 12-month revenue (LTM) of $54.4B and a last 12-month EBITDA of $11.4B.
In the most recent fiscal year, Bayer achieved revenue of $54.9B and an EBITDA of $10.4B.
Bayer expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bayer valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $54.4B | XXX | $54.9B | XXX | XXX | XXX |
| Gross Profit | $29.8B | XXX | $29.8B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $11.4B | XXX | $10.4B | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $7.6B | XXX | $3.9B | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $5.4B | XXX | -$3.0B | XXX | XXX | XXX |
| Net Margin | 10% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $39.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Bayer's stock price is EUR 28 (or $33).
Bayer has current market cap of EUR 27.5B (or $32.4B), and EV of EUR 60.1B (or $70.8B).
See Bayer trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70.8B | $32.4B | XXX | XXX | XXX | XXX | $5.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Bayer has market cap of $32.4B and EV of $70.8B.
Bayer's trades at 1.3x EV/Revenue multiple, and 6.8x EV/EBITDA.
Equity research analysts estimate Bayer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bayer has a P/E ratio of 6.0x.
See valuation multiples for Bayer and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.4B | XXX | $32.4B | XXX | XXX | XXX |
| EV (current) | $70.8B | XXX | $70.8B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.2x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBIT | 9.3x | XXX | 18.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.0x | XXX | -10.8x | XXX | XXX | XXX |
| EV/FCF | 21.1x | XXX | 13.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBayer's last 12 month revenue growth is 0%
Bayer's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Bayer's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bayer's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bayer and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | -5% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bayer acquired XXX companies to date.
Last acquisition by Bayer was XXXXXXXX, XXXXX XXXXX XXXXXX . Bayer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bayer founded? | Bayer was founded in 1863. |
| Where is Bayer headquartered? | Bayer is headquartered in Germany. |
| How many employees does Bayer have? | As of today, Bayer has 92.8K+ employees. |
| Is Bayer publicy listed? | Yes, Bayer is a public company listed on ETR. |
| What is the stock symbol of Bayer? | Bayer trades under BAYN ticker. |
| When did Bayer go public? | Bayer went public in 1953. |
| Who are competitors of Bayer? | Similar companies to Bayer include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bayer? | Bayer's current market cap is $32.4B |
| What is the current revenue of Bayer? | Bayer's last 12 months revenue is $54.4B. |
| What is the current revenue growth of Bayer? | Bayer revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Bayer? | Current revenue multiple of Bayer is 1.3x. |
| Is Bayer profitable? | Yes, Bayer is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bayer? | Bayer's last 12 months EBITDA is $11.4B. |
| What is Bayer's EBITDA margin? | Bayer's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Bayer? | Current EBITDA multiple of Bayer is 6.2x. |
| What is the current FCF of Bayer? | Bayer's last 12 months FCF is $3.4B. |
| What is Bayer's FCF margin? | Bayer's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Bayer? | Current FCF multiple of Bayer is 21.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
